Effectiveness and safety of sacubitril/valsartan in patients with chronic kidney disease: a real-world experience
| Main Author: | |
|---|---|
| Publication Date: | 2023 |
| Other Authors: | , , , , |
| Format: | Article |
| Language: | eng |
| Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| Download full: | http://hdl.handle.net/10451/56406 |
Summary: | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| id |
RCAP_545f448100eb13a9df752c352517593b |
|---|---|
| oai_identifier_str |
oai:repositorio.ulisboa.pt:10451/56406 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| repository_id_str |
https://opendoar.ac.uk/repository/7160 |
| spelling |
Effectiveness and safety of sacubitril/valsartan in patients with chronic kidney disease: a real-world experienceChronic kidney diseaseGlomerular filtration rateHeart failure with reduced ejection fractionAngiotensin receptor neprilysin inhibitorSacubitrilValsartan© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Background: data regarding the effectiveness and safety of sacubitril/valsartan in heart failure and reduced ejection fraction (HFrEF) patients with chronic kidney disease (CKD) are scarse. Objective: to evaluate the effectiveness and safety of sacubitril/valsartan in HFrEF and CKD in a real-world population. Methods: we included consecutive ambulatory HFrEF patients that initiated sacubitril/valsartan between February 2017 and October 2020, stratified by CKD (KDIGO stage 5 excluded). Primary outcomes: the incidence rate per 100 patient-years and the annualized length of stay (LOS) of acute decompensated HF hospitalizations (HFH). Secondary outcomes: all-cause mortality, NYHA improvement, and titration of sacubitril/valsartan. Results: We included 179 patients, 77 with CKD, those being older (72 ± 10 vs. 65 ± 12 years, p < 0.001), had higher NT-proBNP (4623 ± 5266 vs. 1901 ± 1835 pg/mL, p < 0.001), and high anaemia incidence (p < 0.001). After 19 ± 11 months, a significant reduction in HFH adjusted incidence rate (57.5% decrease in CKD vs. 74.6%, p = 0.261) was observed, with 5 days there was a reduction in annualized LOS in both groups (p = 0.319). NYHA improved similarly in both groups (p = 0.670). CKD patients presented non-significant higher all-cause mortality (HR = 2.405, 95%CI: [0.841; 6.879], p = 0.102). Both groups had similar sacubitril/valsartan maximum dose achievement and drug withdrawal. Conclusion: sacubitril/valsartan was effective on reducing HFH and LOS without affecting all-cause mortality in a CKD real-world population.MDPIRepositório da Universidade de LisboaCouto Pereira, Sara CristinaRodrigues, TiagoFerreira, Afonso NunesAgostinho, João R.Pinto, Fausto J.Brito, Dulce2023-02-22T12:31:03Z20232023-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/56406engPereira, S.C., et al. J. Clin. Med. 2023, 12, 133410.3390/jcm120413342077-0383info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-03-17T14:54:09Zoai:repositorio.ulisboa.pt:10451/56406Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T03:28:13.782350Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
| dc.title.none.fl_str_mv |
Effectiveness and safety of sacubitril/valsartan in patients with chronic kidney disease: a real-world experience |
| title |
Effectiveness and safety of sacubitril/valsartan in patients with chronic kidney disease: a real-world experience |
| spellingShingle |
Effectiveness and safety of sacubitril/valsartan in patients with chronic kidney disease: a real-world experience Couto Pereira, Sara Cristina Chronic kidney disease Glomerular filtration rate Heart failure with reduced ejection fraction Angiotensin receptor neprilysin inhibitor Sacubitril Valsartan |
| title_short |
Effectiveness and safety of sacubitril/valsartan in patients with chronic kidney disease: a real-world experience |
| title_full |
Effectiveness and safety of sacubitril/valsartan in patients with chronic kidney disease: a real-world experience |
| title_fullStr |
Effectiveness and safety of sacubitril/valsartan in patients with chronic kidney disease: a real-world experience |
| title_full_unstemmed |
Effectiveness and safety of sacubitril/valsartan in patients with chronic kidney disease: a real-world experience |
| title_sort |
Effectiveness and safety of sacubitril/valsartan in patients with chronic kidney disease: a real-world experience |
| author |
Couto Pereira, Sara Cristina |
| author_facet |
Couto Pereira, Sara Cristina Rodrigues, Tiago Ferreira, Afonso Nunes Agostinho, João R. Pinto, Fausto J. Brito, Dulce |
| author_role |
author |
| author2 |
Rodrigues, Tiago Ferreira, Afonso Nunes Agostinho, João R. Pinto, Fausto J. Brito, Dulce |
| author2_role |
author author author author author |
| dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
| dc.contributor.author.fl_str_mv |
Couto Pereira, Sara Cristina Rodrigues, Tiago Ferreira, Afonso Nunes Agostinho, João R. Pinto, Fausto J. Brito, Dulce |
| dc.subject.por.fl_str_mv |
Chronic kidney disease Glomerular filtration rate Heart failure with reduced ejection fraction Angiotensin receptor neprilysin inhibitor Sacubitril Valsartan |
| topic |
Chronic kidney disease Glomerular filtration rate Heart failure with reduced ejection fraction Angiotensin receptor neprilysin inhibitor Sacubitril Valsartan |
| description |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023-02-22T12:31:03Z 2023 2023-01-01T00:00:00Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/56406 |
| url |
http://hdl.handle.net/10451/56406 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
Pereira, S.C., et al. J. Clin. Med. 2023, 12, 1334 10.3390/jcm12041334 2077-0383 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
| instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
| repository.mail.fl_str_mv |
info@rcaap.pt |
| _version_ |
1833601710822522880 |